ArQule Announces $15.3 Million Registered Direct Offering of Common Stock
29. Februar 2016 06:55 ET
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise...
ArQule to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
15. Februar 2016 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 15, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it will report financial results for the fourth quarter and full year 2015 before the market opens on...
ArQule to Present at Upcoming Investor Conferences
04. Februar 2016 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Provides Proprietary Pipeline Update for AKT Inhibitors
28. Januar 2016 07:30 ET
|
ArQule, Inc.
First cohort dosed in phase 1 trial with ARQ 092 in Proteus syndromeArQule receives Investigational New Drug approval for ARQ 751BURLINGTON, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc....
ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium
25. Januar 2016 07:30 ET
|
ArQule, Inc.
Preliminary analysis of baseline MET incidence in METIV-HCC trial confirms results observed in phase 2 trial BURLINGTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL)...
ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087
15. Dezember 2015 07:30 ET
|
ArQule, Inc.
Orphan drug designation marks significant regulatory milestone for phase 2 trialAdditional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations ...
ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib for Second-Line Hepatocellular Carcinoma
Planned interim analysis expected to occur early in the second quarter of 2016 BURLINGTON, Mass. and PARSIPPANY, N.J., Dec. 10, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) and Daiichi...
ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092
17. November 2015 07:30 ET
|
ArQule, Inc.
ArQule receives orphan drug designation for ARQ 092 in Proteus syndrome BURLINGTON, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) and the National Human Genome Research...
UPDATE -- ArQule Presents Data on Tivantinib and Proprietary Pipeline at AACR-NCI-EORTC Conference
09. November 2015 07:55 ET
|
ArQule, Inc.
Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
ArQule Presents Data on Tivantinib and Propietary Pipeline at AACR-NCI-EORTC Conference
09. November 2015 07:30 ET
|
ArQule, Inc.
Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...